The US FDA has approved the first antibody therapy, erenumab (Aimovig®) for the prevention of migraine headaches.
- Human monoclonal antibody
- Calcitonin-gene related peptide (CGRP) antagonist
- 1-2.5 fewer migraines/month
- Once-monthly self-injectable
- $6900/year before insurance and discounts
- Adverse effects: Injection site reactions and constipation
- 3 Phase III studies w/ 2179 Patients
- LIBERTY, STRIVE ARISE trials
What is a monoclonal antibody drug?
Monoclonal antibody drugs are a novel class of therapeutics that harness antibodies – immune system proteins that normally locate and destroy bacteria, viruses, and toxins – to target malfunctioning molecules in your body.
What is CGRP?
Calcitonin-gene related peptide (CGRP) is a hormone that mediates pain sensation and causes vasodilation. CGRP appears to play a role in the development of migraine headaches.